Mindpeak, a leading provider of AI-supported solutions for pathology, has just announced a Series A financing round totalling 15.3 million US dollars. The round is led by ZEISS Ventures and IFB Innovationsstarter GmbH with the InnoVentureFonds, with participation from AI.FUND and the European Innovation Council Fund, among others.
© Mindpeak: the founders Felix Faber and Dr Tobias Lang
More diagnostic reliability with artificial intelligence
Mindpeak was founded in 2018 by Felix Faber (CEO) and Dr Tobias Lang (CTO). The company develops AI-powered algorithms that support pathologists in routine diagnostics, focussing on the automation of tissue analysis for faster and more accurate results. Mindpeak's platform is designed to increase productivity and diagnostic confidence in clinical laboratories to improve patient outcomes in cancer care.
To date, more than 30,000 patient diagnoses have been supported by the AI solution. Biopharmaceutical companies are also using this technology to predict the efficacy of certain drugs in cancer therapy and to enable targeted treatments. Mindpeak has recently expanded its product portfolio to include additional organs, biomarkers and stains. Strategic partnerships with leading healthcare organisations such as Roche and positive regulatory developments are expected to further strengthen the company's position in the market.
“With this new capital, we will accelerate the development and deployment of our AI solutions, empowering pathologists and researchers with faster, more accurate diagnostic tools. Our goal is to revolutionize cancer diagnostics and ultimately improve patient outcomes.”
Felix Faber, CEO of Mindpeak
